Search

Your search keyword '"van Herpen, Carla M L"' showing total 418 results
Start Over Author "van Herpen, Carla M L"
418 results on '"van Herpen, Carla M L"'

6. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol

Author

Palliatieve Zorg, Pathologie Moleculair, Pathologie Pathologen staf, Cancer, Externen Med. Onco, Geurts, Birgit S, Zeverijn, Laurien J, Leek, Lindsay V M, van Berge Henegouwen, Jade M, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, van de Haar, Joris, van Ommen-Nijhof, Annemiek, Kok, Marleen, Roepman, Paul, Jansen, Anne M L, de Leng, Wendy W J, de Jonge, Maja J A, Hoeben, Ann, van Herpen, Carla M L, Westgeest, Hans M, Wessels, Lodewyk F A, Verheul, Henk M W, Gelderblom, Hans, Voest, Emile E, Palliatieve Zorg, Pathologie Moleculair, Pathologie Pathologen staf, Cancer, Externen Med. Onco, Geurts, Birgit S, Zeverijn, Laurien J, Leek, Lindsay V M, van Berge Henegouwen, Jade M, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, van de Haar, Joris, van Ommen-Nijhof, Annemiek, Kok, Marleen, Roepman, Paul, Jansen, Anne M L, de Leng, Wendy W J, de Jonge, Maja J A, Hoeben, Ann, van Herpen, Carla M L, Westgeest, Hans M, Wessels, Lodewyk F A, Verheul, Henk M W, Gelderblom, Hans, and Voest, Emile E

Published
2024

7. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Author

MS Medische Oncologie, Cancer, Verkerk, Karlijn, Geurts, Birgit S, Zeverijn, Laurien J, van der Noort, Vincent, Verheul, Henk M W, Haanen, John B A G, van der Veldt, Astrid A M, Eskens, Ferry A L M, Aarts, Maureen J B, van Herpen, Carla M L, Jalving, Mathilde, Gietema, Jourik A, Devriese, Lot A, Labots, Mariette, Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Smit, Egbert F, Bloemendal, Haiko J, MS Medische Oncologie, Cancer, Verkerk, Karlijn, Geurts, Birgit S, Zeverijn, Laurien J, van der Noort, Vincent, Verheul, Henk M W, Haanen, John B A G, van der Veldt, Astrid A M, Eskens, Ferry A L M, Aarts, Maureen J B, van Herpen, Carla M L, Jalving, Mathilde, Gietema, Jourik A, Devriese, Lot A, Labots, Mariette, Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Smit, Egbert F, and Bloemendal, Haiko J

Published
2024

10. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Author

Banerji, Udai, van Herpen, Carla M L, Saura, Cristina, Thistlethwaite, Fiona, Lord, Simon, Moreno, Victor, Macpherson, Iain R, Boni, Valentina, Rolfo, Christian, de Vries, Elisabeth G E, Rottey, Sylvie, Geenen, Jill, Eskens, Ferry, Gil-Martin, Marta, Mommers, Ellen C, Koper, Norbert P, and Aftimos, Philippe

Published
2019
Full Text
View/download PDF

13. Pan-cancer whole-genome analyses of metastatic solid tumours

Author

Priestley, Peter, Baber, Jonathan, Lolkema, Martijn P., Steeghs, Neeltje, de Bruijn, Ewart, Shale, Charles, Duyvesteyn, Korneel, Haidari, Susan, van Hoeck, Arne, Onstenk, Wendy, Roepman, Paul, Voda, Mircea, Bloemendal, Haiko J., Tjan-Heijnen, Vivianne C. G., van Herpen, Carla M. L., Labots, Mariette, Witteveen, Petronella O., Smit, Egbert F., Sleijfer, Stefan, Voest, Emile E., and Cuppen, Edwin

Published
2019
Full Text
View/download PDF

15. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., and van Herpen, Carla M. L.

Published
2019
Full Text
View/download PDF

18. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Author

Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.

Subjects
METASTATIC breast cancer, LOBULAR carcinoma, EPIDERMAL growth factor receptors, METASTASIS, HISTOPATHOLOGY, POSITRON emission tomography
Abstract

Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

Author

Willemsen, Annelieke E. C. A. B., de Geus-Oei, Lioe-Fee, de Boer, Maaike, Tol, Jolien, Kamm, Yvonne, de Jong, Paul C., Jonker, Marianne A., Vos, Allert H., Grootjans, Willem, de Groot, Johannes W. B., Mulder, Sasja F., Aarntzen, Erik H. J. G., Gerritsen, Winald R., van Herpen, Carla M. L., and van Erp, Nielka P.

Published
2018
Full Text
View/download PDF

21. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Author

van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, and van Herpen, Carla M. L.

Published
2018
Full Text
View/download PDF

22. The Prognostic Relevance of MRI Characteristics in Myxofibrosarcoma Patients Treated with Neoadjuvant Radiotherapy

Author

van Ravensteijn, Stefan G., primary, Nederkoorn, Maikel J. L., additional, Wal, Tom C. P., additional, Versleijen-Jonkers, Yvonne M. H., additional, Braam, Pètra M., additional, Flucke, Uta E., additional, Bonenkamp, Johannes J., additional, Schreuder, Bart H. W., additional, van Herpen, Carla M. L., additional, de Wilt, Johannes H. W., additional, Desar, Ingrid M. E., additional, and de Rooy, Jacky W. J., additional

Published
2023
Full Text
View/download PDF

23. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Author

Verhoeff, Sarah R, Oosting, Sjoukje F, Elias, Sjoerd G, van Es, Suzanne C, Gerritse, Sophie L, Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M E, Menke-van der Houven van Oordt, C Willemien, van der Veldt, Astrid A M, Arens, Anne I J, Brouwers, Adrienne H, Eisses, Bertha, Mulders, Peter F A, Hoekstra, Otto S, Zwezerijnen, Gerben J C, van der Graaf, Winette T A, Aarntzen, Erik H J G, Oyen, Wim J G, van Herpen, Carla M L, Verhoeff, Sarah R, Oosting, Sjoukje F, Elias, Sjoerd G, van Es, Suzanne C, Gerritse, Sophie L, Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M E, Menke-van der Houven van Oordt, C Willemien, van der Veldt, Astrid A M, Arens, Anne I J, Brouwers, Adrienne H, Eisses, Bertha, Mulders, Peter F A, Hoekstra, Otto S, Zwezerijnen, Gerben J C, van der Graaf, Winette T A, Aarntzen, Erik H J G, Oyen, Wim J G, and van Herpen, Carla M L

Abstract

Purpose: Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with <2 International Metastatic RCC Database Consortium criteria and ≤2 metastatic sites [referred to as watch and wait (“W&W”) criteria]. The IMaging PAtients for Cancer drug SelecTion-Renal Cell Carcinoma study objective was to assess the predictive value of [ 18F]FDG PET/CT and [ 89Zr]Zr-DFO-girentuximab PET/CT for WW duration in patients with mccRCC. Experimental Design: Between February 2015 and March 2018, 48 patients were enrolled, including 40 evaluable patients with good (n ¼ 14) and intermediate (n ¼ 26) prognosis. Baseline contrast-enhanced CT, [ 18F]FDG and [ 89Zr]Zr-DFO-girentuximab PET/CT were performed. Primary endpoint was the time to disease progression warranting systemic treatment. Maximum standardized uptake values (SUV max) were measured using lesions on CT images coregistered to PET/CT.on the basis of median geometric mean SUV max of RECIST-measurable lesions across patients. Results: The median WW time was 16.1 months [95% confidence interval (CI): 9.0–31.7]. The median WW period was shorter in patients with high [ 18F]FDG tumor uptake than those with low uptake (9.0 vs. 36.2 months; HR, 5.6; 95% CI: 2.4–14.7; P < 0.001). Patients with high [ 89Zr]Zr-DFO-girentuximab tumor uptake had a median WW period of 9.3 versus 21.3 months with low uptake (HR, 1.7; 95% CI: 0.9–3.3; P ¼ 0.13). Patients with “W&W criteria” had a longer median WW period of 21.3 compared with patients without: 9.3 months (HR, 1.9; 95% CI: 0.9–3.9; P one-sided ¼ 0.034). Adding [ 18F]FDG uptake to the “W&W criteria” improved the prediction of WW duration (P < 0.001); whereas [ 89Zr]Zr-DFO-girentuximab did not (P ¼ 0.53). Conclusions: In patients with good- o

Published
2023

24. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

Author

Palliatieve Zorg, Pathologie Moleculair, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Externen Med. Onco, Zeverijn, Laurien J, Looze, Eleonora J, Thavaneswaran, Subotheni, van Berge Henegouwen, J Maxime, Simes, Robert J, Hoes, Louisa R, Sjoquist, Katrin M, van der Wijngaart, Hanneke, Sebastian, Lucille, Geurts, Birgit S, Lee, Chee K, de Wit, Gijsbrecht F, Espinoza, David, Roepman, Paul, Lin, Frank P, Jansen, Anne M L, de Leng, Wendy W J, van der Noort, Vincent, Leek, Lindsay V M, de Vos, Filip Y F L, van Herpen, Carla M L, Gelderblom, Hans, Verheul, Henk M W, Thomas, David M, Voest, Emile E, Palliatieve Zorg, Pathologie Moleculair, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Externen Med. Onco, Zeverijn, Laurien J, Looze, Eleonora J, Thavaneswaran, Subotheni, van Berge Henegouwen, J Maxime, Simes, Robert J, Hoes, Louisa R, Sjoquist, Katrin M, van der Wijngaart, Hanneke, Sebastian, Lucille, Geurts, Birgit S, Lee, Chee K, de Wit, Gijsbrecht F, Espinoza, David, Roepman, Paul, Lin, Frank P, Jansen, Anne M L, de Leng, Wendy W J, van der Noort, Vincent, Leek, Lindsay V M, de Vos, Filip Y F L, van Herpen, Carla M L, Gelderblom, Hans, Verheul, Henk M W, Thomas, David M, and Voest, Emile E

Published
2023

25. Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting

Author

Bos, Manouk K., primary, Verhoeff, Sarah R., additional, Oosting, Sjoukje F., additional, Menke-van der Houven van Oordt, Willemien C., additional, Boers, Ruben G., additional, Boers, Joachim B., additional, Gribnau, Joost, additional, Martens, John W. M., additional, Sleijfer, Stefan, additional, van Herpen, Carla M. L., additional, and Wilting, Saskia M., additional

Published
2023
Full Text
View/download PDF

27. Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity

Author

Hoge, Rien H. L., primary, Detert Oude Weme, Suzan E. H., additional, Vervenne, Walter L., additional, van Berlo-van de Laar, Inge R. F., additional, van Herpen, Carla M. L., additional, Roorda, Laurens, additional, Mathôt, Ron A. A., additional, Jacobs, Maartje S., additional, van Erp, Nielka P., additional, and Jansman, Frank G. A., additional

Published
2022
Full Text
View/download PDF

28. Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

Author

Boon, Eline, van Boxtel, Wim, Buter, Jan, Baatenburg de Jong, Robert J., van Es, Robert J. J., Bel, Miranda, Fiets, Edward, Oosting, Sjoukje F., Slingerland, Marije, Hoeben, Ann, Tesselaar, Margot E. T., Jonker, Marianne A., Flucke, Uta E., van der Graaf, Winette T. A., and van Herpen, Carla M. L.

Published
2018
Full Text
View/download PDF

30. Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients

Author

Lassche, Gerben, primary, van Helvert, Sjoerd, additional, Eijkelenboom, Astrid, additional, Tjan, Martijn J. H., additional, Jansen, Erik A. M., additional, van Cleef, Patricia H. J., additional, Verhaegh, Gerald W., additional, Kamping, Eveline J., additional, Grünberg, Katrien, additional, van Engen-van Grunsven, Adriana C. H., additional, Ligtenberg, Marjolijn J. L., additional, and van Herpen, Carla M. L., additional

Published
2022
Full Text
View/download PDF

31. Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review

Author

Kolsteren, Evie E. M., primary, Deuning-Smit, Esther, additional, Chu, Alanna K., additional, van der Hoeven, Yvonne C. W., additional, Prins, Judith B., additional, van der Graaf, Winette T. A., additional, van Herpen, Carla M. L., additional, van Oort, Inge M., additional, Lebel, Sophie, additional, Thewes, Belinda, additional, Kwakkenbos, Linda, additional, and Custers, José A. E., additional

Published
2022
Full Text
View/download PDF

36. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-Mutant Melanoma

Author

MS Medische Oncologie, Cancer, Schuler, Martin, Zimmer, Lisa, Kim, Kevin B, Sosman, Jeffrey A, Ascierto, Paolo A, Postow, Michael A, De Vos, Filip, van Herpen, Carla M L, Carlino, Matteo S, Johnson, Douglas B, Berking, Carola, Reddy, Micaela B, Harney, Allison S, Berlin, Jordan D, Amaria, Rodabe N, MS Medische Oncologie, Cancer, Schuler, Martin, Zimmer, Lisa, Kim, Kevin B, Sosman, Jeffrey A, Ascierto, Paolo A, Postow, Michael A, De Vos, Filip, van Herpen, Carla M L, Carlino, Matteo S, Johnson, Douglas B, Berking, Carola, Reddy, Micaela B, Harney, Allison S, Berlin, Jordan D, and Amaria, Rodabe N

Published
2022

37. Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from Genomics - Guided Treatment

Author

Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Apotheek O&O&O, MS Medische Oncologie, Externen Med. Onco, CMM, CMM Groep Cuppen, Hoes, Louisa R, van Berge Henegouwen, Jade M, van der Wijngaart, Hanneke, Zeverijn, Laurien J, van der Velden, Daphne L, van de Haar, Joris, Roepman, Paul, de Leng, Wendy J, Jansen, Anne M L, van Werkhoven, Erik, van der Noort, Vincent, Huitema, Alwin D R, Gort, Eelke H, de Groot, Jan Willem B, Kerver, Emile D, de Groot, Derk Jan, Erdkamp, Frans, Beerepoot, Laurens V, Hendriks, Mathijs P, Smit, Egbert F, van der Graaf, Winette T A, van Herpen, Carla M L, Labots, Mariette, Hoeben, Ann, Morreau, Hans, Lolkema, Martijn P, Cuppen, Edwin, Gelderblom, Hans J, Verheul, Henk M W, Voest, Emile E, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Apotheek O&O&O, MS Medische Oncologie, Externen Med. Onco, CMM, CMM Groep Cuppen, Hoes, Louisa R, van Berge Henegouwen, Jade M, van der Wijngaart, Hanneke, Zeverijn, Laurien J, van der Velden, Daphne L, van de Haar, Joris, Roepman, Paul, de Leng, Wendy J, Jansen, Anne M L, van Werkhoven, Erik, van der Noort, Vincent, Huitema, Alwin D R, Gort, Eelke H, de Groot, Jan Willem B, Kerver, Emile D, de Groot, Derk Jan, Erdkamp, Frans, Beerepoot, Laurens V, Hendriks, Mathijs P, Smit, Egbert F, van der Graaf, Winette T A, van Herpen, Carla M L, Labots, Mariette, Hoeben, Ann, Morreau, Hans, Lolkema, Martijn P, Cuppen, Edwin, Gelderblom, Hans J, Verheul, Henk M W, and Voest, Emile E

Published
2022

38. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Author

Boon, Eline, van der Graaf, Winette T. A., Gelderblom, Hans, Tesselaar, Margot E. T., van Es, Robert J. J., Oosting, Sjoukje F., de Bree, Remco, van Meerten, Esther, Hoeben, Ann, Smeele, Ludi E., Willems, Stefan M., Witjes, Max J. H., Buter, Jan, Baatenburg de Jong, Robert J., Flucke, Uta E., Peer, Petronella G. M., Bovée, Judith V. M. G., and Van Herpen, Carla M. L.

Published
2017
Full Text
View/download PDF

49. Additional file 2 of Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study

Author

van Oosterhout, Sanne P. C., Ermers, Daisy J. M., Ploos van Amstel, Floor K., van Herpen, Carla M. L., Schoon, Yvonne, Perry, Marieke, van Geel, Maartje, Kuip, Evelien J. M., and Engels, Yvonne

Subjects
ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, ComputingMilieux_COMPUTERSANDSOCIETY
Abstract

Additional file 2. Codebook interviews family caregivers. Microsoft Word document (DOC). In this additional file the final coding scheme for the interviews with the family caregivers is reported.

Published
2021
Full Text
View/download PDF

50. Additional file 1 of Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study

Author

van Oosterhout, Sanne P. C., Ermers, Daisy J. M., Ploos van Amstel, Floor K., van Herpen, Carla M. L., Schoon, Yvonne, Perry, Marieke, van Geel, Maartje, Kuip, Evelien J. M., and Engels, Yvonne

Subjects
Data_FILES, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, ComputingMilieux_COMPUTERSANDSOCIETY
Abstract

Additional file 1. Topic list family caregivers. Microsoft Word document (DOC). In this additional file the topic list for the interviews with the family caregivers is reported.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results